Johnson & Johnson and Pfizer say they will sell U.S. marketing rights for the heartburn drug Zantac to Boehringer Ingelheim Pharmaceuticals for $509.5 million as part of J&J's planned acquisition of Pfizer's consumer health business. The sale is intended to facilitate Federal Trade Commission approval of the $16.6 billion J&J-Pfizer deal.

Full Story:

Related Summaries